Genmab will not file Arzerra for NHL after Phase III trial failure
This article was originally published in Scrip
Executive Summary
Genmab will not file its lead drug candidate, the anti-CD20 monoclonal antibody drug Arzerra (ofatumumab), for what would have been its biggest indication to date – refractory follicular non-Hodgkin’s lymphoma (NHL) – after the pivotal Phase III trial in this population failed to meet its primary response rate endpoint. The result also led the company to cut its 2009 revenue forecast and to a 30% fall in its share price on August 18th.